Literature DB >> 11489693

Use of cadaveric solvent-dehydrated fascia lata for cystocele repair--preliminary results.

A Groutz1, D C Chaikin, E Theusen, J G Blaivas.   

Abstract

OBJECTIVES: To present a surgical technique in which cadaveric fascia lata is used for cystocele repair.
METHODS: Twenty-one consecutive women (mean age 67 +/- 10 years) with severe cystocele were prospectively enrolled. All patients underwent meticulous clinical and urodynamic preoperative evaluations. Solvent-dehydrated, Tutoplast-processed, cadaveric fascia lata was used for cystocele repair. The fascia was anchored transversally between the bilateral arcus tendineus and the cardinal and uterosacral ligaments. Standard endopelvic plication was performed thereafter as a second layer. Patients with overt or occult sphincteric incontinence underwent concomitant pubovaginal sling (PVS) surgery as well, using the same material. The main outcome measures included recurrent urogenital prolapse, persistent or de novo urinary incontinence (stress or urge), and dyspareunia.
RESULTS: Of the 21 patients, 19 underwent concomitant PVS, 3 concomitant vaginal hysterectomy, and 8 posterior colporrhaphy in addition to their cystocele repair. The mean follow-up was 20.1 +/- 6.7 months (range 12 to 30). No postoperative complications related to the material or technique occurred. None of the patients developed a recurrent cystocele. Two patients (9%), one of whom underwent concomitant posterior colporrhaphy, developed mild recto-enterocele at 4 to 6 months postoperatively. Six patients underwent concomitant PVS for occult sphincteric incontinence. None developed postoperative stress incontinence. Thirteen other patients underwent concomitant PVS for overt sphincteric incontinence. All but two were stress-continent postoperatively. One half of the patients with preoperative urge or mixed incontinence had persistent urge incontinence postoperatively. None of the patients developed postoperative de novo urge incontinence or dyspareunia.
CONCLUSIONS: The use of solvent-dehydrated cadaveric fascia lata for cystocele repair, as well as PVS, is associated with encouraging short and medium-term results. Long-term follow-up is needed to evaluate whether these results are durable.

Entities:  

Mesh:

Year:  2001        PMID: 11489693     DOI: 10.1016/s0090-4295(01)01177-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  Anatomical outcome and quality of life following posterior vaginal wall prolapse repair using collagen xenograft.

Authors:  Daniel Altman; Annika López; Catharina Gustafsson; Christian Falconer; Johan Nordenstam; Jan Zetterström
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-04-05

2.  Cadaveric fascia lata.

Authors:  Pamela A Moalli
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-06

Review 3.  Pelvic organ prolapse surgery and bladder function.

Authors:  Kaven Baessler; Christopher Maher
Journal:  Int Urogynecol J       Date:  2013-11       Impact factor: 2.894

4.  Patient characteristics and management of dermal allograft extrusions.

Authors:  Natalie L Drake; Alison C Weidner; George D Webster; Cindy L Amundsen
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-01-13

5.  Comparison of solvent-dehydrated allograft dermis and autograft rectus fascia for pubovaginal sling: questionnaire-based analysis.

Authors:  Rahmi Onur; Ajay Singla; Kathleen C Kobashi
Journal:  Int Urol Nephrol       Date:  2007-07-03       Impact factor: 2.370

Review 6.  Anterior vaginal compartment surgery.

Authors:  Christopher Maher
Journal:  Int Urogynecol J       Date:  2013-11       Impact factor: 2.894

Review 7.  The use of graft materials in anterior compartment pelvic reconstruction.

Authors:  J Sean Begley; Kathleen C Kobashi
Journal:  Curr Urol Rep       Date:  2004-10       Impact factor: 2.862

8.  Use of grafts in pelvic reconstructive surgery.

Authors:  Myung Jae Jeon; Sang Wook Bai
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.